Industry Payments Common for Physician Peer Reviewers of Top Journals
FRIDAY, Oct. 11, 2024 -- More than half of U.S. physician peer reviewers for the most influential medical journals receive industry payments, according to a research letter published online Oct. 10 in the Journal of the American Medical Association.
David-Dan Nguyen, M.P.H., from the University of Toronto, and colleagues characterized payments by drug and medical device manufacturers to U.S. peer reviewers of major medical journals. The analysis included 1,962 U.S.-based physician peer reviewers (2020 to 2022) for The BMJ, JAMA, The Lancet, and the New England Journal of Medicine.
The researchers found that 58.9 percent of identified peer reviewers received at least one industry payment, including general payments (54.0 percent) and research payments (31.8 percent). Overall, reviewers received $1.06 billion in industry payments during the study period, including $1.00 billion (94.0 percent) to individuals or their institutions and $64.18 million (6.0 percent) in general payments. Consulting fees accounted for $34.31 million, and speaking compensation unrelated to continuing medical education programs accounted for $11.80 million. Among reviewers receiving such payments, the median general payment was $7,614 and the median research payment was $153,173. There were significant payment differences seen by sex and specialty.
"Additional research and transparency regarding industry payments in the peer review process are needed," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Lung Cancer Screening Beneficial to Age 80 for Candidates Fit for Surgery
FRIDAY, Sept. 12, 2025 -- People aged 75 to 80 years at last screen who are diagnosed with screen-detected lung cancer (LC) have lower overall survival, but those undergoing...
Sex Differences Seen in Characteristics, Course of Schizophrenia, Bipolar Disorder
FRIDAY, Sept. 12, 2025 -- Significant sex differences are seen in the characteristics and course of schizophrenia (SZ) and bipolar disorder (BD), according to a study published...
Potentially Inappropriate Medications Linked to Frailty at Cancer Diagnosis
FRIDAY, Sept. 12, 2025 -- For patients with newly diagnosed cancer, an increasing number of potentially inappropriate medications (PIMs), as identified by the Geriatric Oncology...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.